Monitoring of Anticoagulants

Our monitoring assays cover the entire spectrum of anticoagulants. The anticoagulants used nowadays can be divided into:

• Vitamin K antagonists such as Marcumar^®
• Heparins (UFH, LMWH) and heparinoids, e.g. danaparoid sodium (Orgaran^®) and fondaparinux (Arixtra^®) 
• Direct Xa inhibitors such as apixaban (Eliquis^®), rivaroxaban (Xarelto^®) and edoxaban (Lixiana^®)
• Direct thrombin inhibitors (anti-IIa) such as argatroban (Argatra^®), dabigatran (Pradaxa^®), hirudin and bivalirudin (Angiox^®)  

Anti-factor Xa / Anti-factor IIa

As for factor Xa testing, our assay BIOPHEN™ Heparin LRT is a product that stands out, as it not only suitable for determining the anti-factor Xa activity of heparin and its analogues but also for measuring all three direct Xa inhibitors using the same calibration curve.      

As for anti-factor IIa testing, our chromogenic assay BIOPHEN™ DTI and our clotting assay HEMOCLOT™ DTI have proven to be particularly effective.

Direct oral anticoagulants (DOACs)

In coagulation disorder therapy, the direct oral anticoagulants (DOACs) apixaban (Eliquis^®), rivaroxaban (Xarelto^®), dabigatran (Pradaxa^®) and edoxaban (Lixiana^®) have established themselves increasingly, but often impose laboratories a diagnostical problem: If present in plasma samples, they interfere with a big number of coagulation assays. This issue is solved by DOAC-Remove, activated carbon, specially formulated and presented in tablet form. 

For more products and information, please see our folder (German version).

Heparin induced thrombocytopenia (HIT-II)

Heparin induced thrombocytopenia type II (HIT-II) is a side effect of heparin treatment. Our ZYMUTEST HIA ELISA kits cover the whole range of heparin-induced antibodies involved in the development of a HIT or a heparin induced thrombocytopenia with thrombosis (HITT). Moreover, findings so far show highly positive results for vaccine-induced immune thrombotic thrombocytopenia (VITT):

ZYMUTEST™ HIA, IgG: Specifically detects heparin-dependent antibodies of the IgG isotype, which are reported as those with the strongest association with the clinical complications of a HIT/HITT. This assay therefore allows confirmation of a HIT/HITT diagnosis or its clinical suspicion.   

ZYMUTEST™ HIA, IgGAM Screening: Globally measures all heparin-dependent antibodies (isotypes IgG, IgM and IgA) and therefore offers the highest sensitivity. This assay is proposed as screening, as an early identification of heparin-treated patients presenting a risk of HIT/HITT. 

More products and information on heparin-induced thrombocytopenia (HIT-II) can be found in our folder (German version).